Home  »  Equities Feed   »  Liquidia Corporation (LQDA) Stock Plunged 12.60% T...

Liquidia Corporation (LQDA) Stock Plunged 12.60% Today, Here’s Why

Liquidia Corporation (LQDA) stock plummeted 12.60% in the current-market trading session at the price of $5.41 after proposing a public offering of its common stock shares.

LQDA is a biopharmaceutical firm that develops products using its proprietary PRINT technology. The company has devised YUTREPIA inhalation powder to treat pulmonary arterial hypertension. PAH platform commercializes pharmaceutical products for rare disease patients.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.

Sponsored

LQDA Proposed Public Offering

On 12th April 2022, LQDA announced to initiate the public offering of its 9,803,922 common stock shares. Additionally, LQDA anticipates granting the underwriters an option to buy an additional 15 percent of the common stock shares at the public price. The shares had been offered at the public offering price of UE$5.10 for gross proceeds of roughly US$50.0M before subtracting underwriting discounts and other expenses.

The shares are being offered under the shelf registration statement on Form S-3 filed previously with the SEC on 16th December 2020 and became effective on 23rd December 2020. The offering is subject to market closing conditions, and there are no details about the closure, actual size, and conditions of the offering. BofA Securities is serving as the only book-running supervisor for the proposed public offering.

LQDA Market Outlook

LQDA stock had achieved its maximum objectives last year by growing sales of its Treprostinil injection and acquiring approval for YUTREPIA. Currently, the firm is advancing its position in the current Hatch-Waxman case and bolstering the balance sheet. The company is expecting to deliver YUTREPIA to all PAH patients by 2022. Looking onwards, LQDA expects to earn over US$1B from inhaled treprostinil as the demand for the product inflates.

Conclusion

Over the last 90 days, the LQDA’s earnings have moved 10.5 percent higher. In the past 52 weeks, the company’s shares were risen up to 129.24 percent, indicating a positive performance trend. That’s the reason the stock is grabbing the attention of multiple investors.

Leave a Comment

Your email address will not be published.

Related Videos

Related Posts

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam